Zhejiang Jingxin Pharmaceutical Co., Ltd. (811142) News

Express News | On the afternoon of the first day of the 2026 National Reimbursement Drug List (NRDL) negotiations: Pfizer, Innovent Bio, and other domestic and foreign companies enter the venue

The 2026 National Reimbursement Drug List (NRDL) negotiations officially commenced today. Reporters from The Science and Technology Innovation Board Daily learned on-site that around 1:15 PM, participating companies included Hengrui Pharma, Dongyangguang Pharmaceutical, Zhuhai Rundu Pharmaceutical, CSPC Pharma, Shanghai Pharmaceuticals, Innovent Bio, Jingxin Pharmaceutical, Boehringer Ingelheim, Novo-Nordisk A/S, and Pfizer. Companies entering the venue this morning included Everest Medicines, Zai Lab, 3SBio, Joincare Pharmaceutical, and Kanion Pharmaceutical.

BreakingsSep 5 13:37

Q&A | Jingxin Pharmaceutical: The company is proceeding with its H-share listing as planned

Gelonghui, August 24 – An investor asked Jingxin Pharmaceutical on an interactive platform whether it was true that the company’s H-share prospectus, submitted on February 11, 2026, would expire after six months on August 11, 2026, and whether this meant the company would no longer issue new shares in Hong Kong. Jingxin Pharmaceutical responded that it is proceeding normally with its H-share listing.

Gelonghui FinanceAug 24 15:57

IPO News | Jingxin Pharmaceutical (002020.SZ) Hong Kong IPO Prospectus Has Lapsed

, Zhejiang Jingxin Pharmaceutical Co., Ltd. (short name: Jingxin Pharmaceutical, 002020.SZ) submitted its Hong Kong IPO prospectus on February 11, 2026, which lapsed six months later on August 11, 2026.

Zhitong FinanceAug 11 06:16

Express News | Jingxin Pharmaceutical: Plans to Repurchase Shares Worth RMB 100–200 Million for Cancellation and Capital Reduction

Jingxin Pharmaceutical announced that the company intends to use its own funds to repurchase shares via centralized bidding for cancellation and reduction of registered capital. The total repurchase amount will range between RMB 100 million and RMB 200 million, with a repurchase price not exceeding RMB 19 per share. This is expected to result in the repurchase of 5.2632–10.5263 million shares, representing approximately 0.61%–1.22% of the company's total share capital. The repurchase will be carried out within 12 months from the date of shareholder approval. The repurchase plan has already been approved by both the Board of Directors and the shareholders’ meeting, and the company has opened a dedicated securities account for the repurchase. Additionally, risks associated with this repurchase include potential failure to implement the plan smoothly, the need to amend or terminate the plan, and creditors demanding early repayment of debts.

BreakingsJul 20 18:26

Express News | Market Close: STAR 50 Index Plunges 7.7% as AI Computing Hardware and Semiconductor Sectors Undergo Broad Correction

Markets traded lower throughout the session, with all three major indices opening lower and continuing to decline. The STAR 50 Index plunged 7.7%. A clear divergence emerged between the weighted and unweighted market lines, reflecting weaker performance among large-cap stocks. Combined trading volume on the Shanghai and Shenzhen stock exchanges totaled RMB 3.45 trillion, down RMB 209.5 billion from the previous trading day. Market sentiment was fragmented, with more than 3,100 individual stocks posting losses. By sector, humanoid robotics-related stocks showed notable strength: Fulai New Materials rose by its daily limit for two consecutive sessions; Fenglong Shares gained its second daily limit in three trading days; Riying Electronics and Yingfeng Shares both hit their daily trading limits. The non-ferrous metals sector strengthened, with Xianglu Tungsten, Chifeng Gold, and Zhaogold Mining all closing at their daily upside limits. Innovative drug developers bucked the downtrend, with Hainan Pharmaceutical achieving six daily limits in eight sessions, Menovo Pharma securing two straight daily limits, and Shijiazhuang Pharma Jingfeng and Jingxin Pharmaceutical both reaching their daily trading caps. On the downside, semiconductor equipment stocks continued their correction, with NAURA and Jinhaitong both hitting their daily downside limits. AI computing hardware names suffered broad declines, as Dongshan Precision, Gigadevice, and Accelink Technologies all closed at their daily downside limits. At market close, the Shanghai Composite Index fell 2.03%, the Shenzhen Component Index dropped 3.85%, and the ChiNext Price Index slid 5.71%.

BreakingsJul 2 15:01

Company Q&A | Jingxin Pharmaceutical: The company holds a 5.88% equity stake in Hu Qing Yu Tang Pharmaceutical Holdings.

Gelonghui, June 15 — An investor asked Jingxin Pharmaceutical on an interactive platform: Hu Qing Yu Tang has undergone shareholding reform. What percentage of Hu Qing Yu Tang does the company hold? How much in dividends has Hu Qing Yu Tang distributed to the company over the past three years? Jingxin Pharmaceutical replied that the company holds a 5.88% equity stake in Hu Qing Yu Tang Pharmaceutical Holding.

Gelonghui FinanceJun 15 17:32

Company Q&A | Jingxin Pharmaceutical: Cariprazine Hydrochloride is still in the approval and registration process.

Gelonghui, June 15 | An investor asked Jingxin Pharmaceutical on an interactive platform whether the company's key near-innovative drug, cariprazine hydrochloride, has already been removed from the review queue and entered the administrative approval and certificate issuance stage. As a major product, industry insiders widely estimate its peak nationwide sales could approach RMB 5 billion, with the company enjoying nearly three years of market exclusivity. Can the company achieve expected sales of RMB 2 billion? Jingxin Pharmaceutical responded that cariprazine hydrochloride is still undergoing the regulatory approval process, and if successfully approved for marketing, the company will actively advance its commercialization.

Gelonghui FinanceJun 15 17:31

New IPO News | Jingxin Pharmaceutical (002020.SZ) Plans Hong Kong IPO; China Securities Regulatory Commission Requests Additional Clarification on Regulatory Procedures Related to Overseas Investments Involving Its Foreign Subsidiaries

The China Securities Regulatory Commission (CSRC) issued the 'Supplementary Materials Requirements for Overseas Listing Filings (May 25, 2026 – May 29, 2026).'

Zhitong FinanceMay 29 19:21